Pontifax Management 4 G.P. (2015) Ltd. - 17 Apr 2025 SCHEDULE 13D/A Report for Keros Therapeutics, Inc. Common Stock, Par Value $0.0001 Per Share (KROS)

Filing Manager: Pontifax Management 4 G.P. (2015) Ltd.
Reporting Manager: Pontifax Management 4 GP (2015) Ltd.
Security: Keros Therapeutics, Inc. Common Stock, Par Value $0.0001 Per Share
Symbol: KROS
Shares outstanding: 40,570,602 shares
Disclosed Ownership: 4,787,331 shares
Ownership: 12%
Form type: SCHEDULE 13D/A
Filing time: 18 Apr 2025, 17:10:53 UTC
Date of event: 17 Apr 2025
Next filing: 16 Oct 2025
SEC: View on sec.gov

Reporting Managers (6)

Name	Ownership	Shares Owned	shared voting power	Signature	Title	CIK
Pontifax Management 4 GP (2015) Ltd.	12%	4,787,331	4,787,331	/s/ Tomer Kariv	Tomer Kariv, Chief Executive Officer	0001726334
Pontifax (Israel) IV, L.P.	5.6%	2,284,612	2,284,612	/s/ Tomer Kariv	Tomer Kariv, Chief Executive Officer
Pontifax (Cayman) IV, L.P.	2.8%	1,121,045	1,121,045	/s/ Tomer Kariv	Tomer Kariv, Chief Executive Officer
Pontifax (China) IV, L.P.	3%	1,226,412	1,226,412	/s/ Tomer Kariv	Tomer Kariv, Chief Executive Officer
Pontifax Late Stage Fund L.P.	0.4%	155,262	155,262	/s/ Asaf Shinar	Asaf Shinar, Chief Financial Officer
Pontifax Late Stage GP Ltd.	0.4%	155,262	155,262	/s/ Asaf Shinar	Asaf Shinar, Chief Financial Officer